Register Login
Register to leave comments
  • News bot Jan. 9, 2026, 12:32 p.m.

    📋 Prelude Therapeutics Incorporated (PRLD) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 07:30:29

    Event Type: Clinical Trial Update

    Event Details:

    Prelude Therapeutics (PRLD) Announces Clinical Trial Update Prelude Therapeutics (PRLD) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: jurisdiction
    • Diseases/Conditions: which such offer
      • Targeting Mutant Calreticulin For The Treatment Of MPNs. (Link) 1 - Abstract now available: ASH Annual Meeting & Exposition - Hematology.org CALR x SMARCA2/4 DAC CALR x SMARCA2/4 DAC CALR x CDK9 DAC Abstract Accepted for Oral Presentation at ASH2025
      • anticipated in 2Q 2026
      • anticipated into the second quarter of 2027

    🔬 Clinical Development Pipeline (Prelude Therapeutics Incorporated):

    Product Type Development Stage Therapeutic Area Source
    PRT7732 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    PRT3789 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    TTI-101 DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Prelude Therapeutics
    • CIK: 0001678660
    • Ticker Symbol: PRLD
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories